Dainippon Sumitomo Seeks Added Uses For AmBisome Anti-Fungal
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma has filed for additional indications for its anti-fungal AmBisome (amphotericin). The company is believed to be asking for several additional fungi to be added to the three it now has approval for, but it would not say how many or which. The drug already has Japanese approval for treating aspergillus, candida and cryptococcus. Dainippon applied under a system that could allow approval of the additional uses without being subjected to new clinical trials. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.